- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00030342
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
A Phase I/II Study Of Interleukin-12-Primed Activated T Cells In Combination With 5FU, GM-CSF And Interferon Alfa-2b In Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of biological therapy combined with chemotherapy in treating patients who have metastatic kidney cancer or colorectal cancer.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
- Determine the safety of a repeat course of interleukin-12-primed activated T cells (12ATC) in combination with fluorouracil, sargramostim (GM-CSF), and interferon alfa-2b in patients with metastatic renal cell or colorectal carcinoma.
- Determine the clinical responses of patients treated with this regimen.
- Determine the efficacy of 12ATC in these patients.
- Determine whether there are changes in immunologic parameters related to 12ATC as measured by lymphocyte phenotype and cytokine secretion in these patients.
- Determine the correlation between clinical responses in patients treated with this regimen and in vitro immune functions of lymphocytes.
OUTLINE: Patients are stratified according to disease type (renal cell carcinoma vs colorectal carcinoma).
Patients receive sargramostim (GM-CSF) subcutaneously (SC) daily on days 1-5 and then undergo collection of autologous peripheral blood mononuclear cells (PBMC) on days 6 and 7 of week 1. The PBMC are treated ex vivo to form interleukin-12-primed activated T cells (12ATC).
Patients receive fluorouracil IV over 24 hours on day 6 of week 2 and interferon alfa-2b SC and GM-CSF SC 3 times weekly on weeks 3-5. Patients receive 12ATC IV over 15-30 minutes twice weekly and interferon alfa-2b SC (at least 24 hours after 12ATC infusion) once weekly on weeks 6-8. Patients with complete or partial response or stable disease at 3 weeks after the last 12ATC infusion may receive an additional 8-week course as above.
Patients are followed every 2-3 months for 1 year and then every 6 months for 2 years or at any time when the physical examination or symptoms are suspicious for tumor progression.
PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study within 2-3 years.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed metastatic renal cell carcinoma or colorectal carcinoma, meeting 1 of the following criteria:
- Obtained no benefit from prior standard or salvage therapy
- Ineligible for standard therapy because of concurrent illness
- Declined standard therapy
At least 1 site of measurable disease that can be measured in at least 1 dimension
- At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan
- No untreated or unstable, treated brain metastasis
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC at least 4,000/mm^3
- Granulocyte count at least 2,000/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
- No coagulation disorders
Hepatic:
- Bilirubin no greater than 2.5 mg/dL*
- ALT/AST less than 3 times upper limit of normal*
- PT no greater than 1.5 times control (unless therapeutically anticoagulated)
- PTT less than 1.5 times control (unless therapeutically anticoagulated) NOTE: *Patients whose cancer has led to values that do not fall within the above ranges may be eligible at the discretion of the investigators
Renal:
- Creatinine no greater than 2.0 mg/dL* NOTE: *Patients whose cancer has led to values that do not fall within the above range may be eligible at the discretion of the investigators
Cardiovascular:
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No thrombophlebitis
Pulmonary:
- FEV_1 and FVC at least 65% predicted
- No uncontrolled pulmonary embolism
Other:
- No other malignancy within the past 5 years except resected basal cell skin cancer or carcinoma in situ of the cervix
- No prior allergic reactions attributed to compounds of similar chemical or biologic composition to interleukin-12-primed activated T cells or other study agents
- No active autoimmune disease
- No uncontrolled thyroid abnormalities
- No ongoing or active infection
- No other uncontrolled concurrent illness
- No psychiatric illness or social situations that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for up to 2 years after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- More than 4 weeks since prior immunotherapy
Chemotherapy:
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy:
- At least 4 weeks since prior steroid therapy or steroid-containing compounds
- At least 2 weeks since prior topical or inhaled steroids
Radiotherapy:
- More than 4 weeks since prior radiotherapy and recovered
Surgery:
- More than 4 weeks since prior major surgery
Other:
- No other concurrent investigational agents
- No other concurrent commercial anticancer agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
Überleben, gemessen mit der Kaplan-Meier-Methode nach 5 Jahren
|
Response as measured by RECIST guidelines and Kaplan-Meier method at 5 years
|
Safety as measured by NCI common toxicity table at study completion
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: John P. Hanson, MD, St. Luke's Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Urologische Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Nierenerkrankungen
- Urologische Erkrankungen
- Adenokarzinom
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmerkrankungen
- Darmerkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Nierentumoren
- Karzinom, Nierenzelle
- Kolorektale Neubildungen
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Interferone
- Interferon-alpha
- Fluorouracil
- Sargramostim
Andere Studien-ID-Nummern
- STLMC-IMM-0104
- CDR0000069153 (Registrierungskennung: PDQ (Physician Data Query))
- STLMC-L-01108
- NCI-V01-1686
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur rekombinantes Interferon alfa
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenTumore des Gehirns und des zentralen NervensystemsVereinigte Staaten
-
Pusan National University HospitalUnbekanntChronische Hepatitis BKorea, Republik von
-
National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
Columbia UniversityMerck Sharp & Dohme LLCZurückgezogenNierenerkrankung im Endstadium | Hepatitis-C-Infektion
-
Merck Sharp & Dohme LLCBeendet
-
Merck Sharp & Dohme LLCBeendet
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenBlasenkrebs | HarnröhrenkrebsVereinigte Staaten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BeendetBrustkrebs | Metastasierender KrebsVereinigte Staaten
-
Hoffmann-La RocheAbgeschlossenNierenzellkarzinom | Chronische myeloische Leukämie | Bösartiges MelanomKanada, Indien, Bulgarien, Russische Föderation, Spanien, Südafrika, Slowakei
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendiertNeoplasma hämatopoetischer und lymphoider Zellen | Bösartiges solides Neoplasma | Symptomatische COVID-19-Infektion LaborbestätigtVereinigte Staaten